SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Feb 25

PMID 36837589

Authors

Jonathan C H Chan

Michael C Y Chan

Affiliations

Soon will be listed here.

Abstract

Sodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause death), and renal disease (delay the onset of dialysis) regardless of diabetic status. The consistent cardiorenal benefits observed in major landmark trials have resulted in the rapid adoption of SGLT2i therapy not only in diabetes guidelines but also cardiovascular and renal guidelines.

Citing Articles

Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice-A Cross-Sectional Study.

Iordan L, Avram V, Timar B, Sturza A, Popescu S, Albai O Medicina (Kaunas). 2025; 60(12.

PMID: 39768854 PMC: 11678545. DOI: 10.3390/medicina60121974.

Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure.

Li F, Baheti R, Jin M, Xiong W, Duan J, Fang P Diabetol Metab Syndr. 2024; 16(1):299.

PMID: 39696647 PMC: 11657645. DOI: 10.1186/s13098-024-01553-z.

SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat.

Vlachakis P, Theofilis P, Tousoulis D World J Cardiol. 2024; 16(11):669-672.

PMID: 39600990 PMC: 11586729. DOI: 10.4330/wjc.v16.i11.669.

Autonomic modulation by SGLT2i or DPP4i in patients with diabetes favors cardiovascular outcomes as revealed by skin sympathetic nerve activity.

Chen J, Lin C, Lo M, Lin L, Chang H, Liu G Front Pharmacol. 2024; 15:1424544.

PMID: 39139635 PMC: 11319125. DOI: 10.3389/fphar.2024.1424544.

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.

Stanciu G, Ababei D, Solcan C, Bild V, Ciobica A, Beschea Chiriac S Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004485 PMC: 10674192. DOI: 10.3390/ph16111620.

References

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Lopaschuk G, Verma S . Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020; 5(6):632-644. PMC: 7315190. DOI: 10.1016/j.jacbts.2020.02.004. View

Gallo L, Wright E, Vallon V . Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015; 12(2):78-89. PMC: 5886707. DOI: 10.1177/1479164114561992. View

. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S):S1-S127. DOI: 10.1016/j.kint.2022.06.008. View

OMeara E, McDonald M, Chan M, Ducharme A, Ezekowitz J, Giannetti N . CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020; 36(2):159-169. DOI: 10.1016/j.cjca.2019.11.036. View

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

Neal B, Perkovic V, Matthews D, Mahaffey K, Fulcher G, Meininger G . Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(3):387-393. PMC: 5348724. DOI: 10.1111/dom.12829. View

Ehrenkranz J, Lewis N, Kahn C, Roth J . Phlorizin: a review. Diabetes Metab Res Rev. 2004; 21(1):31-8. DOI: 10.1002/dmrr.532. View

10.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

11.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

12.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

13.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

14.

Frias J, Guja C, Hardy E, Ahmed A, Dong F, Ohman P . Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised.... Lancet Diabetes Endocrinol. 2016; 4(12):1004-1016. DOI: 10.1016/S2213-8587(16)30267-4. View

15.

McGill J, Subramanian S . Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol. 2019; 124 Suppl 1:S45-S52. DOI: 10.1016/j.amjcard.2019.10.029. View

16.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Furtado R . Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118.038868. View

17.

Petrie M, Verma S, Docherty K, Inzucchi S, Anand I, Belohlavek J . Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020; 323(14):1353-1368. PMC: 7157181. DOI: 10.1001/jama.2020.1906. View

18.

Docherty K, McMurray J . SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. Eur J Heart Fail. 2020; 23(1):27-30. PMC: 8048660. DOI: 10.1002/ejhf.2075. View

19.

Korayem G, Alshaya O, Alghamdi A, Alanazi S, Almutib R, Alsaileek M . The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. Front Public Health. 2022; 10:1031306. PMC: 9673169. DOI: 10.3389/fpubh.2022.1031306. View

20.

Rodbard H, Rosenstock J, Canani L, Deerochanawong C, Gumprecht J, Lindberg S . Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019; 42(12):2272-2281. DOI: 10.2337/dc19-0883. View